Wolverine Trading
AXSM icon

Wolverine Trading’s Axsome Therapeutics AXSM Stock Holding History

Wolverine Trading’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.14M Buy
18,157
+548
+3% +$61.7K ﹤0.01% 2121
2025
Q2 		$1.82M Buy
17,609
+8,743
+99% +$926K ﹤0.01% 1777
2025
Q1 		$1.05M Sell
8,866
-2,256
-20% -$257K ﹤0.01% 2195
2024
Q4 		$943K Sell
11,122
-2,928
-21% -$269K ﹤0.01% 2713
2024
Q3 		$1.26M Buy
+14,050
New +$1.23M ﹤0.01% 2127
2024
Q2 		– Sell
-3,885
Closed -$288K – 4467
2024
Q1 		$310K Sell
3,885
-1,173
-23% -$98.5K ﹤0.01% 3319
2023
Q4 		$403K Sell
5,058
-534
-10% -$35.7K ﹤0.01% 3173
2023
Q3 		$391K Sell
5,592
-2,227
-28% -$166K ﹤0.01% 3010
2023
Q2 		$572K Buy
+7,819
New +$577K ﹤0.01% 2476
2023
Q1 		– Sell
-3,920
Closed -$258K – 4204
2022
Q4 		$302K Sell
3,920
-2,659
-40% -$159K ﹤0.01% 2750
2022
Q3 		$290K Buy
+6,579
New +$329K ﹤0.01% 3178

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wolverine Trading's AXSM Position: Q3 2025 in Review

Wolverine Trading increased its Axsome Therapeutics (AXSM) stake by 3.1% in Q3 2025, buying an estimated $61.7K and bringing the position to 18,157 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2121.

Wolverine Trading first reported a position in AXSM in Q3 2022 and has held it in 11 quarters since. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Wolverine Trading held 18,157 shares of Axsome Therapeutics worth $2.14M as of Q3 2025.
  • Wolverine Trading bought 548 Axsome Therapeutics shares in Q3 2025, an estimated $61.7K.
  • Axsome Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #2121 holding.
  • Wolverine Trading first reported a position in Axsome Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.